MARITZA PELLEGRINI: Open Payments
NPI 1972285104 · BRICK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$753 in 60 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $122 · 2025 $753
Food & beverage: $753
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 41 | $397 |
| Alkermes, Inc. | 4 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Lilly USA, LLC | 2 | $44 |
| Neurocrine BioSciences, Inc. | 2 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Neos Therapeutics, LP | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
Products named: VRAYLAR, ARISTADA, REXULTI, AMYVID, INGREZZA, AUSTEDO XR, CAPLYTA, TRINTELLIX.
Industry payments across NJ — which companies pay providers there.
